



Dr. med. Laure Thouvenin

Oncologie Médicale
Médecine Interne Générale

Sprachen

FR,EN

Ausbildung

seit 2024	Participation in the <i>certificate of advanced studies</i> (CAS) "Integrative and complementary medicine in hospitals and the community"
2023	FMH title of specialist in internal medicine
2021	FMH title of specialist in medical oncology
2006–2012	Geneva University of Medicine, federal diploma in medicine

Berufserfahrung

2021–2024	Senior consultant in the medical oncology department of the University Hospitals of Geneva (inpatient, outpatient)
2016–2021	Outpatient medical oncology (Geneva University Hospitals), including one year in clinical research (research unit of the Dr Henri Dubois-Ferrière Dinu Lipatti Foundation)
2012–2016	General internal medicine (Hôpital de la Tour, then University Hospitals of Geneva) (in-hospital, emergency, intensive care)

Mitgliedschaften

- European Society for Medical Oncology (ESMO)
- Association Suisse des Médecins (FMH) (en cours)
- Association des Médecins du canton de Genève (AMGe) (en cours)
- Société Suisse d'Oncologie Médicale (SSOM) (en cours)

Publikationen

Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland. [S Colomer-Lahiguera](#), [C Canella](#), [S Giacomini](#), [K Lê Van](#), [C Pedrazzani](#), [M Naegele](#), [L Thouvenin](#), [A O'Meara Stern](#), [R Condorelli](#), [T Corbière](#), [C Witt](#), [M Eicher](#), [K Ribl](#). Support Care Cancer. 2023 Jun 22;31(7):410. doi: 10.1007/s00520-023-07871-8.

[Differential impact of tamoxifen and aromatase inhibitors on thrombin generation : the prospective HEMOBREAST cohort](#). Blondon M, Bodmer A, Thouvenin L, Lecompte T, Righini M, Fontana P, Casini A. Blood Adv. 2022 May 10;6(9):2884-2892. doi: 10.1182/bloodadvances.2021006623

[Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.](#) Thouvenin L, Charrier M, Clement S, Christinat Y, Tille JC, Frigeri M, Homicsko K, Michielin O, Bodmer A, Chappuis PO, McKee TA, Tsantoulis P. Gynecol Oncol Rep. 2021 May 19;37:100787. doi: 10.1016/j.gore.2021.100787. eCollection 2021 Aug

[Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis : a case-series and narrative review.](#) Thouvenin L, Olivier T, Banna G, Addeo A, Friedlaender A. Ther Adv Drug Saf. 2021 Mar 29;12:20420986211004745. doi: 10.1177/20420986211004745. eCollection 2021

[A new hope in the treatment of hepatocellular carcinoma.](#) Thouvenin L, Friedlaender A. Rev Med Suisse. 2020 May 27;16(695):1074-1078

[Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.](#) Frisone D, Charrier M, Clement S, Christinat Y, Thouvenin L, Homicsko K, Michielin O, Bodmer A, Chappuis PO, McKee TA, Tsantoulis P. Cancer Biol Ther. 2020;21(3):197-202. doi: 10.1080/15384047.2019.1685291. Epub 2019 Nov 10

[Monoclonal gammopathies: from MGUS to multiple myeloma.](#) Thouvenin L, Lang N. Rev Med Suisse. 2019 May 15;15(651):1022-1026

Akkreditierung

[Clinique Générale-Beaulieu](#)

Fachgebiete

[Krebstherapien und Onkologie](#)

[Innere Medizin](#)

Kontakt

Générale-Beaulieu Swiss Oncology Network

Chemin de Beau-Soleil 20

1206 Genève

T 022 839 57 00

cabinet.thouvenin@beaulieu.ch

[vCard herunterladen](#)